Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Manjunath Nimmakayalu Image

      Manjunath Nimmakayalu, Ph.D.

      School of Health Professions, Division of Chief Academic Officer

      About Dr. Manjunath Nimmakayalu

      Dr. Manjunath Nimmakayalu is an Associate Professor with professional experience in teaching, research and diagnostics in Cytogenetics and Medical Genetics. He earned his PhD in Human Genetics from Bangalore University, India and completed postdoctoral training at Institut fur Human Genetik, University of Gottingen, Germany, and Yale University School of Medicine concentrating on developing techniques in Human molecular cytogenetics. His academic career spans three decades, in research, diagnostics and a prior faculty appointment at Gulf Medical University, Ajman, UAE.

      Dr. Nimmakayalu is board-certified in Cytogenetics by the American Society for Clinical Pathology (ASCP). His interests His interests are introducing newer cytogenomic technologies in clinical and research, and later with an emphasis on integrating these techniques in graduate education. He has contributed his research data through peer-reviewed publications and book chapters.

      Based on his experience as educator, Dr. Nimmakayalu has played a key in implementing the problem-based curricula in cytogenetics and cytogenomics in the Graduate program. He has so far mentored ~60 undergraduate and graduate students and contributes as a reviewer for journals like Frontiers in Genetics, Journal of AGT, Molecular cytogenetics and Journal of Rare disorders.

      Read More

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, School of Health Professions, Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Assistant Professor, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Associate Professor, School of Health Professions, University of Texas, MD Anderson cancer Ctr, Houston, TX

      Research Interests

      My research is mostly collaborative and focused mostly on developing novel approaches using molecular cytogenetic techniques that would benefit in research and diagnostics. I have developed low cost fluorescent dUTPs for labeling procedures used in Multicolor and other FISH techniques, mapped few genes on human and mouse samples which were of clinical significance. And developed novel approaches to map the unstable chromosome 22 rearrangements for ex: dual color primed in-situ hybridization (PRINS); dissecting rearranged chromosomes by laser capture microscopy and used fiber FISH to map break points. Validation of high-resolution array platform for clinical diagnosis and to analyze chromosomally normal patients with intellectual disability to identify cryptic copy number variations. I continue to apply molecular cytogenetics techniques like FISH to study the evolution and heterogeneity of oncogenic amplifications in human cancers.

      Education & Training

      Degree-Granting Education

      1984Bangalore University, Bangalore, IN, Zoology/ Animal Physiology, M.S. in Zoology
      1994Bangalore University, Bangalore, Karnataka, IN, Cancer Cytogenetics, Ph.D. in Human Genetics

      Postgraduate Training

      1998-2002Post Doctoral Training, Human Molecular Genetics, Yale University, New Haven, Connecticut
      1994-1996Research Fellowship, Human Molecular Genetics, Institut fur Human Genetik, Gottingen

      Licenses & Certifications

      2012American Society of Clinical Pathology (CG)

      Experience & Service

      Faculty Academic Appointments

      Assistant Professor, School of Health Professions, University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2025

      Assistant Professor, Allied Health Sciences, Gulf Medical University, Ajman, AJMAN, 2014 - 2018

      Other Professional Positions

      Member/In charge of the Ambassadors, AGT Ambassador Program, International ambassadors, Association of Genetic Technologists (AGT), Houston, TX, 2023 - Present

      Member, Public Relations committee, Association of Genetic Technologists (AGT), Houston, TX, 2022 - Present

      TSAHP conference abstracts reviewer, Texas Society of Allied Health Professions, Houston, TX, 2021 - Present

      Associate Director, Genetics, CSI Laboratories, Alpharetta, GA, 2012 - 2013

      Associate Research Scientist, Div. of Medical Genetics, Department of Pediatrics, University of Iowa, Iowa City, IA, 2006 - 2011

      Research Associate, Children's Hospital of Philadelphia, Philadelphia, PA, 2002 - 2006

      Intramural Institutional Committee Activities

      Member, CCSG Career Enhancement Travel Award, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, MS thesis committee for Cytogenetics and Cytogenomics track, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Teaching faculty, Duke TIP Scholar Summer workshop, The University of Texas MD Anderson Cancer Center, 2020 - 2022

      Member, Pandemic Lab Integration Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Diagnostic Genetics and Genomics Advisory Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, SHP Academic Coordinator committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, SHP Scholarship application review committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Diagnostic Genetics - Education coordinator interview committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, King Foundation High School Summer Program, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Diagnostic Genetics and Genomics – Admissions committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, King Foundation High School Applicant Review committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Cytogenetic Technology (CGT) Admissions committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, School of Health professions -Academic standing Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Cytogenetic Technology (CGT) Advisory committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

      Extramural Institutional Committee Activities

      Member, FY22 Assessment Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Editorial Activities

      Reviewer, Discover Medicine, 2025 - Present

      Reviewer, Journal of Rare diseases, 2025 - Present

      Reviewer, Molecular Cytogenetics, 2025 - Present

      Blog writer for the International Ambassador Program and in charge International Public Relations Committee, Journal of Association of Genetic Technologists, 2023 - Present

      Guest Editor, Frontiers in Genetics, 2023 - Present

      Member Review board, Journal of Association of Genetic Technologists, 2019 - Present

      Honors & Awards

      2022 - 2023Nominated Faculty member - University of Texas MD Anderson Cancer Ctr Chapter of the Alpha Eta Society, Alpha ETA Society, MD Anderson Cancer Ctr Chapter
      2020Texas Society of Allied Health Professions Research Grant Award, Texas Society of Allied Health Professions
      1994 - 1996Visiting Scientist Fellowship, German Ministry for Education and Research, (BMBF)

      Professional Memberships

      Association of Genetic Technologists

      2023 - Present

      Cancer Genomics Consortium

      2022 - Present

      Association of Genetic Technologists

      2021 - Present

      Texas Society of Allied Health Professions

      2020 - Present

      Texas Society for Allied Health Professions

      2020 - Present

      Association of Genetic Technologists

      2019 - Present

      American Society of Human Genetics

      2019 - 2021

      Association of Genetic Technologists

      2019 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2024. Characterization and Identification of MYC Rearrangement Partners in Large B-Cell Lymphoma (LBCL) Cell Lines. Poster. MDACC Department of Pathology and Laboratory Medicine Annual Research Day. Houston, Texas, US.
      2. 2024. Unraveling the Genetic Alterations in large B-Cell Lymphoma. Poster. MDA Education Week. Houston, Texas, US.
      3. 2024. Recurrent and non-recurrent chromosomal abnormalities. Invited. Seminar in Health Care. Houston, Texas, US.
      4. 2023. Recurrent and non-recurrent chromosomal abnormalities. Invited. Seminar in Health Care. Houston, Texas, US.
      5. 2022. Integrated Research based project in the Cytogenetic and Cytogenomics track of the Diagnostic Genetics and Genomics program. Conference. MDA Education week. Houston, TX, US.

      Regional Presentations

      1. 2023. Project-Based Integrated Core Curriculum for Cytogenetics and Cytogenomics Track of the Graduate Program in Diagnostic Genetics and Genomics. Poster. TEACH - S Symposium. Houston, TX, US.
      2. 2021. Introduction of multiple ligation probe amplification (MLPA) PCR based assay in the cytogenetics and cytogenomics curriculum of the diagnostic genetics and genomics (DGG) program. Conference. Annual meeting Texas Society of Allied Health Professions (TSAHP). Virutal, TX, US.

      National Presentations

      1. 2026. Optical genome mapping improves detection of cryptic structural variants in chronic myelomonocytic leukemia. Poster. Annual meeting Cancer Genetics Consortium. Houston, Texas, US.
      2. 2026. Genomic Profiling of ALK-Negative ALCL Cell Lines DL-40 and Fe-PD by Optical Genome Mapping. Poster. Annual Meeting Cancer Genetics Consortium. Houston, Texas, US.
      3. 2026. Molecular cytogenetic characterization of patient derived T-ALL cell lines. Poster. Joint Annual Meeting 2026 (ASCLS, AGT & SAFMLS). St. Louis, Missouri, US.
      4. 2026. Chromoanagenesis Independently Predicts Poorer Survival in Myelodysplastic Syndromes with Complex Karyotypes. Invited. Annual meeting USCAP 2026. San Antonio, Texas, US.
      5. 2026. Improving Detection of Variant MECOM Rearrangements Through Optical Genome Mapping and Repurposed Targeted RNA-Seq Data. Invited. American College of Medical Genetics annual meeting. Baltimore, MD, US.
      6. 2025. Confirmation PIDD1 and p90RSK Mediate Radiation-Induced Genomic Instability in Endothelial Cells: Implications for Cardiovascular Disease. Invited. SfRBM Conference 2025. Washington DC, US.
      7. 2025. Cytogenomic Characterization of ALK-negative ALCL Cell Lines DL-40 and Fe-PD. Poster. Annual meeting Cancer Genomics Consortium. Houston, Texas, US.
      8. 2025. Molecular Cytogenetic Characterization of Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma Cancer Cell Lines. Poster. Joint Annual Meeting (AGT, ACLS) 2025. Sacramento, California, US.
      9. 2025. Molecular Cytogenetic Characterization of Lung Carcinoma Cell Lines. Poster. Joint Annual Meeting 2025 (ASCLS, AGT & SAFMLS). Sacramento, California, US.
      10. 2025. Chromoanagenesis Independently Predicts Poorer Survival in Myelodysplastic Syndromes with Complex Karyotypes. United States and Canadian Academy of Pathology (USCAP 2026). San Antonio, Texas, US.
      11. 2024. Genomic Characterization of the T-ALL Cell Line CCRF-CEM Using Optical Genome Mapping and Nanopore Sequencing. Poster. Annual meeting Cancer Genomics Consortium. St Louis, Missouri, US.
      12. 2024. Molecular Cytogenetic Characterization of Hepatocellular Carcinoma Cell Lines. Poster. Joint Annual Meeting 2024 (ASCLS, AGT & SAFMLS). Virtual meeting - Pittsburgh, PA, US.
      13. 2024. Cytogenomic characterization of a T-ALL patient derived cell line CCRF -CEM using novel genomic technologies. Poster. Joint Annual Meeting 2024 (ASCLS, AGT & SAFMLS). Virtual meeting - Pittsburgh, PA, US.
      14. 2023. Investigation of TRPS1 Copy number variations/Rearrangements in Breast Cancer Using Homebrewed FISH Probe Set. Poster. Joint Annual Meeting 2023 (ASCLS, AGT & SAFMLS). Providence, RI, US.
      15. 2023. The role of mutant NPM1 condensates in HOX gene regulation in Acute Myeloid Leukemia. Poster. Joint Annual Meeting 2023 (ASCLS, AGT & SAFMLS). Virtual meeting, RI, US.
      16. 2023. Understanding the Genetic Diversity of Glioblastoma: Gene Amplification in Extrachromosomal DNA and Homogeneously Staining Regions. Poster. Joint Annual Meeting 2023 (ASCLS, AGT & SAFMLS). Providence, RI, US.
      17. 2023. Insights into the Genetic Heterogeneity of Glioblastoma: Gene Amplification in Extrachromosomal DNA and Homogeneously Staining Regions. Poster. Joint Annual Meeting 2023 (ASCLS, AGT & SAFMLS). Providence, RI, US.
      18. 2023. Molecular Cytogenetic Characterization of Non-Hodgkin’s Lymphoma (NHL) Cancer Cell Lines. Poster. Joint Annual Meeting 2023 (ASCLS, AGT & SAFMLS). Providence, RI, US.
      19. 2022. Molecular Cytogenetic Characterization of Cell Lines with Complex Karyotypes. Poster. Joint Annual meeting (ASCLS, AGT & SAFMLS) 2022. Grand Rapids, MI, US.
      20. 2022. Characterization of Large B-Cell Lymphoma Cell Lines. Poster. Joint Annual Meeting 2022 (ASCLS, AGT & SAFMLS). Grand Rapids, MI, US.
      21. 2022. Cytogenetic Analysis for Characterization of Large B-Cell Lymphoma Cell Lines. Poster. Joint Annual Meeting 2022 (ASCLS, AGT & SAFMLS). Virtual Meeting, KY, US.
      22. 2021. High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. Conference. Annual meeting of American Society of Hematology (ASH). Virtual Meeting, US.
      23. 2021. Clinical Validation of Illumina Infinium CytoSNP-850K SNP-Array for Routine Clinical Copy Number Profiling of Hematological Malignancies. Conference. Cancer Genome Consortium. Virtual Meeting, US.
      24. 2021. Cytogenetic Analysis of the Cell Line BT549. Poster. Joint Annual Meeting 2021 (ASCLS, AGT & SAFMLS). Virtual meeting, KY, US.
      25. 2021. Cytogenetic Analysis of a Triple Negative Breast Cancer MDA-MB-231 Cell Line. Poster. Joint Annual Meeting 2021 (ASCLS, AGT & SAFMLS),. Virtual meeting, KY, US.
      26. 2021. Molecular Cytogenetic Studies to Evaluate Evolution and Heterogeneity of Oncogene Amplifications in Solid Tumors. Poster. Joint Meeting 2021 (ASCLS & AGT). Virtual Meeting, KY, US.
      27. 2021. Cytogenetic Characterization of HCC70 Cell Line. Poster. Joint Annual Meeting 2021 (ASCLS, AGT & SAFMLS). Virtual meeting, KY, US.
      28. 2021. Studying a Triple Negative Breast Cancer Cell Line MDA-MB-468 Using Cytogenetic and Molecular Techniques. Poster. Joint Annual Meeting 2021 (ASCLS, AGT & SAFMLS). Virtual meeting, KY, US.
      29. 2021. Characterization of large B-cell lymphoma cell lines for cancer research. Poster. Joint Annual Meeting 2021 (ASCLS, AGT & SAFMLS). Virtual meeting, KY, US.
      30. 2020. Investigation of MECOM rearrangement in a Myelodysplastic Syndrome (MDS) Case with t(3;6)(q26.2;q21) using two sets of break apart probe. Poster. Joint Meeting 2020 (ASCLS & AGT). Virtual, US.
      31. 2020. Molecular Cytogenetic Characterization of CCRF-CEM Cell Line. Poster. Joint Meeting 2020 (ASCLS and AGT). Virtual Meeting, US.
      32. 2010. Utilization of high-density oligonucleotide array to analyze patients with developmental delay and congenital anomalies. Conference. American Society of Human Genetics (ASHG). Washington D.C, DC, US.
      33. 2010. A novel 4p16.3 microduplication characterized by aCGH with new phenotypic features. A. B. Cyr, M. Nimmakayalu. Conference. American Society of Human Genetics (ASHG). Washington DC, DC, US.
      34. 2008. Utilization of high-resolution genome-wide oligonucleotide microarrays to detect copy number variations. Conference. American Society of Human Genetics (ASHG). Philadelphia, PA, US.
      35. 2008. Molecular analysis of translocation breakpoints in a novel t(1;9) in a patient with isolated cardiac defect. Conference. American Society of Human Genetics (ASHG). Philadelphia, PA, US.
      36. 2004. Pericentric inv(22): Another Low Copy Repeats (LCR) Mediated Recurrent Abnormality?. Conference. Biennial American Cytogenetics Conference. Stevenson, WA, US.
      37. 2003. Analysis of a translocation breakpoint by FISH and PRINS: a molecular cytogenetic approach. Conference. American Society of Human Genetics (ASHG). Los Angeles, CA, US.
      38. 2003. Phenotypic and Molecular characterization of distal 19q trisomy detected by FISH. Conference. American Society of Human Genetics (ASHG). Los Angeles, CA, US.
      39. 2000. Mapping of a mosaic deletion of the short arm of chromosome 7 (7p15.3 to 7p21.1). Conference. American Society of Human Genetics (ASHG). Philadelphia, PA, US.
      40. 2000. Molecular characterization of microscopically visible deletion of 7q11.23 to q21.11. Conference. Annual meeting American Society of Human Genetics (ASHG). Philadelphia, PA, US.
      41. 1999. A simple fluornucleotide coupling method for M-FISH analysis of patients associated with MR and Autism. Conference. Annual meeting American Society of Human Genetics. San Francisco, CA, US.

      International Presentations

      1. 2017. Application of a rapid assay detects a 1.4 Mb atypical WBS deletion in a patient referred with congenital heart defect. Conference. Gulf Medical University, Ajman, UAE. Abu Dhabi, AE.
      Read More
      Less

      Selected Publications

      Peer-Reviewed Articles

      1. Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros L, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306–2316, 2022. e-Pub 2022. PMID: 35915143.
      2. Song J, Yu A, Munoz D, Han S, Nimmakayalu M, Hu PC, Dong J. Impact of Using Median vs. Mean in Calculating ERBB2 FISH Results in Breast Cancer. Cancer Med J 4(3):87-96, 2021. e-Pub 2021. PMID: 34095900.
      3. Khouzam RA, RRao SP, Venkatesh GH, Zeinelabdin NA, Buart S, Meylan M, Nimmakayalu M, Terry S, Chouaib S. An eight-gene hypoxia signature predicts survival in pancreatic cancer and is associated with an immunosuppressed tumor microenvironment. Front Immunol 12, 2021. e-Pub 2021. PMID: 34093582.
      4. Akdemir KC, Akdemir KC, Le VT, Le VT, Kim JM, Kim JM, Killcoyne S, Killcoyne S, King DA, King DA, Lin YP, Lin YP, Tian Y, Tian Y, Inoue A, Inoue A, Amin SB, Amin SB, Robinson FS, Robinson FS, Nimmakayalu M, Nimmakayalu M, Herrera RE, Herrera RE, Lynn EJ, Lynn EJ, Chan K, Chan K, Seth S, Seth S, Klimczak LJ, Klimczak LJ, Gerstung M, Gerstung M, Gordenin DA, Gordenin DA, O'Brien J, O'Brien J, Li L, Li L, Deribe YL, Deribe YL, Verhaak RG, Verhaak RG, Campbell PJ, Campbell PJ, Fitzgerald R, Fitzgerald R, Morrison AJ, Morrison AJ, Dixon JR, Dixon JR, Futreal PA, Futreal PA. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nat Genet 52(11):1178-1188, 2020. e-Pub 2020. PMID: 33020667.
      5. Nimmakayalu M, Horton VK, Darbro B, Patil SR, Alsayouf H, Keppler-Noreuil K, Shchelochkov OA. Apparent germline mosaicism for a novel 19p13.13 deletion disrupting NFIX and CACNA1A. Am J Med Genet A 161A(5):1105-9, 2013. e-Pub 2013. PMID: 23495138.
      6. Nimmakayalu M, Noble N, Horton VK, Willing M, Copeland S, Sheffield V, Nagy PL, Wassink T, Patil S, Shchelochkov OA. 2q24 deletions: further characterization of clinical findings and their relation to the SCN cluster. Am J Med Genet A, 2012. e-Pub 2012. PMID: 23023937.
      7. Cyr AB, Nimmakayalu M, Longmuir SQ, Patil SR, Keppler-Noreuil KM, Shchelochkov OA. A novel 4p16.3 microduplication distal to WHSC1 and WHSC2 characterized by oligonucleotide array with new phenotypic features. Am J Med Genet A 155A(9):2224-8, 2011. e-Pub 2011. PMID: 21815251.
      8. Nimmakayalu M, Major H, Sheffield V, Solomon DH, Smith RJ, Patil SR, Shchelochkov OA. Microdeletion of 17q22q23.2 encompassing TBX2 and TBX4 in a patient with congenital microcephaly, thyroid duct cyst, sensorineural hearing loss, and pulmonary hypertension. Am J Med Genet A 155A(2):418-23, 2011. e-Pub 2011. PMID: 21271665.
      9. Li MM, Nimmakayalu M, Mercer D, Andersson HC, Emanuel BS. Characterization of a cryptic 3.3 Mb deletion in a patient with a "balanced t(15;22) translocation". Am J Med Genet A 146(3):368–375, 2008. e-Pub 2008. PMID: 18203177.
      10. Nimmakayalu M, Nimmakayalu MA, Jalali GR, Hacker AM, Vorstman J, Conforto Duffy D, Medne L, Emanuel BS. A palindrome-driven complex rearrangement of 22q11.2 and 8q24.1 elucidated using novel technologies. Genome Res 17(4):470–481, 2007. e-Pub 2007. PMID: 17351131.
      11. Tamim H Shaikh, O'Connor RJ, Pierpont ME, McGrath J, Hacker AM, Nimmakayalu M, Geiger E, Emanuel BS, Saitta SC. Low copy repeats mediate distal chromosome 22q11.2 deletions: sequence analysis predicts breakpoint mechanisms. Genome Res 17(4):482–491, 2007. e-Pub 2007. PMID: 17351135.
      12. Li P, Zhang H C, Huff S, Nimmakayalu M, Qumsiyeh M, Yu J, Szekely A, Xu T, Pober BR. Karyotype-phenotype insights from 11q14.1-q23.2 interstitial deletions: FZD4 haploinsufficiency and exudative vitreoretinopathy in a patient with a complex chromosome rearrangement. Am J Med Genet A 140(24):2721-9, 2006. e-Pub 2006. PMID: 17103440.
      13. Ming JE, Geiger E, James AC, Ciprero KL, Nimmakayalu M, Zhang Y, Huang A, Vaddi M, Rappaport E, Zackai EH, Shaikh TH. Rapid detection of submicroscopic chromosomal rearrangements in children with multiple congenital anomalies using high density oligonucleotide arrays. Hum Mutat 5:467-73, 2006. e-Pub 2006. PMID: 16619270.
      14. Zhang HZ, Li P, Wang D, Huff S,, Nimmakayalu M, Qumsiyeh M, Pober BR. FOXC1 gene deletion is associated with eye anomalies in ring chromosome 6. Am J Med Genet A 124A(3):280-87, 2004. e-Pub 2004. PMID: 14708101.
      15. Nimmakayalu M, A L Gotter, T H. Shaikh, B S. Emanuel. A novel sequence-based approach to localize translocation breakpoints identifies the molecular basis of a t(4;22). Hum Mol Genet 12(21):2817–2825, 2003. e-Pub 2003. PMID: 12952865.
      16. Pei Hui, John G Howe, Jill Crouch, Nimmakayalu M, M B Qumsiyeh, G Tallini, S D Flynn, B R Smith. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry. Leuk Lymphoma 44(8):1385-94, 2003. e-Pub 2003. PMID: 12952233.
      17. J Kone, J Arroyo, T Savinelli, S Lin, K Boyd, Y Wu, M Nimmakayalu, NG Copeland, NA Jenkins, M Qumsiyeh, P Hu, A Prescott, H Wu, L Yang, B Roe, AS Perkins. F-MuLV acceleration of myelomonocytic tumorigenesis in SV40 large T antigen transgenic mice is accompanied by retroviral insertion at Fli1 and a novel locus, Fim4. Leukemia 16(9):1827–1834, 2002. e-Pub 2002. PMID: 12200699.
      18. Stankiewicz P, J Rujner,, C Löffler, A Krüger, Nimmakayalu M, B Piłacik, M Krajewska-Walasek, A Gutkowska, I Hansmann, I Giannakudis. Alagille syndrome associated with a paracentric inversion 20p12.2p13 disrupting the JAG1 gene. Am J Med Genet 103(2):166-71, 2001. e-Pub 2001. PMID: 11568926.
      19. D Bockenhauer, Nimmakayalu M, D C Ward, S A Goldstein, P G Gallagher. Genomic organization and chromosomal localization of the murine 2 P domain potassium channel gene Kcnk8: conservation of gene structure in 2 P domain potassium channels. Cytogenet Cell Genet 261(2):365-372, 2000. e-Pub 2000. PMID: 1167025.
      20. Y. H. Yang, Y. H. Chen, C. Y. Zhang, Nimmakayalu M, D. C. Ward, S. Weissman. Cloning and Characterization of Two Mouse Genes with Homology to the Yeast Sir2 Gene. Genomics 69(3):355-369, 2000. e-Pub 2000. PMID: 11056054.
      21. Nimmakayalu M, O Henegariu, D C Ward, P Bray-Ward. Simple method for preparation of fluor/hapten-labeled dUTP. Biotechniques 28(3):518-522, 2000. e-Pub 2000. PMID: 10723566.
      22. D Cao, M Nimmakayalu, F Wang, D Zhang, R E Handschumacher, P Bray-Ward, G Pizzorno. Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene. Cancer Res 10(59(19)):4997-5001, 1999. e-Pub 1999. PMID: 10519414.
      23. H. Wang, G. Chatterjee, J. J. Meyer, C-J. Liu, Nimmakayalu M, P. Bray-Ward, P. Lengyel*. Characteristics of three homologous 202 genes (Ifi202a, Ifi202b, and Ifi202c) from the murine interferon-activatable gene 200 cluster. Genomics 60:281–294, 1999. e-Pub 1999. PMID: 10493828.
      24. B Ghosh, H C Jacobs, L M Wiedemann, A Brown, F K Bedford, Nimmakayalu M, D C Ward, C W Bogue. Genomic structure, cDNA mapping, and chromosomal localization of the mouse homeobox gene, Hex. Mamm Genome 10:1023-5, 1999. e-Pub 1999. PMID: 10501975.
      25. Jacob A N, Nimmakayalu M, P Bray-Ward, R P Kandpal. Molecular cloning of a zinc finger gene eZNF from a human inner ear cDNA library, and in situ expression pattern of its mouse homologue in mouse inner ear. Somat Cell Mol Genet, 1998. e-Pub 1998. PMID: 9919311.

      Other Articles

      1. N D Theise, Nimmakayalu M, R Gardner, P B Illei, G Morgan, L Teperman, O Henegariu, D S Krause Liver from bone marrow in humans. Hepatology 32:11-16, 2000. PMID: 10869283.
      2. O Cremona, Nimmakayalu M, C Haffner, P Bray-Ward, D C Ward, P De Camilli Assignment of SYNJ1 to human chromosome 21q22.2 and Synj12 to the murine homologous region on chromosome 16C3-4 by in situ hybridization. Cytogenet Cell Genet 88((1-2)):89-90, 2000. PMID: 10773674.
      3. Nimmakayalu M, P Bray-Ward, S A Goldstein, P G Gallagher Assignment of the 2P domain, acid-sensitive potassium channel OAT1 gene KCNK3 to human chromosome bands 2p24.1-->p23.3 and murine 5B by in situ hybridization. Cytogenet Cell Genet 86:242-243, 1999. PMID: 10575216.

      Abstracts

      1. Alcassab H, Sasaki K, Hammond D, Bataller A, Beck D, Kadia T, Montalban-Bravo G, Chien K, Medeiros L, Kantarjian H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Garcia-Manero G, Kanagal-Shamanna R. Characterization of MDS and CMML Patients Harboring Trisomy 8 Abnormality: Clinical, Autoimmune, and Mutational Features. American Society of Hematology 142(Supplement 1), 2023. e-Pub 2023.
      2. I Martin-Barrio, B Zhao, L Ye, X Liu, P Hu, A. Kalia, Y Lissanu, M Nimmakayalu, K C. Akdemir. Insights into the genetic heterogeneity of glioblastoma: gene amplification in ecDNA and HSR. Cancer Genetics Consortium Volumes 278–279(Supplement 1):20-21, 2023. e-Pub 2023.
      3. Rush D, Luthra R, Hu P, Bueso-Ramos C, Nimmakayalu M, Tang Z, Patel K, Lucas FS, JamesOzenci, Puthooran S, JeffreyMedeiros L, Barkoh B, Raju S, Ahmed N, RKanagal-Shamanna. Clinical validation of Infinium CytoSNP-850K SNP-Array for routine copy number profiling of hematological malignancies. Cancer Genetics Consortium 260-261(Supplement 1):16-17, 2022. e-Pub 2022.
      4. Yang H, Garcia-Manero G, Montalban-Bravo G, Chien KS, Kalia A, Tang Z, Wei Y, Nimmakayalu M, Rush D, Mallampati S, Kantarjian H, Luthra R, Medeiros L, Kanagal-Shamanna R. High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. American Society of Hematology Blood 138(Supplement), 2021. e-Pub 2021.
      5. Cyr A, Nimmakayalu M, Major H, Patil S, Keppler-Noreuil K, Shchelochkov O. A novel 4p16.3 microduplication characterized by aCGH with new phenotypic features. American Journal of Human genetics, 2010. e-Pub 2010.
      6. Nimmakayalu M, Major H, Qian Q, Shchelochkov O, Darbro B, Rheeden R, Hulseberg D, Sheffield V, Nagy P, Patil S. Utilization of high-density oligonucleotide array to analyze patients with developmental delay and congenital anomalies. American Journal of Human genetics, 2010. e-Pub 2010.
      7. Nimmakayalu M, Major H, Qining Q, Rhedeen R, Hulseberg D, Sheffield V, Nagy P, Patil S. Utilization of high resolution genome-wide oligonucleotide microarrays to detect copy number variations. American Journal of Human genetics, 2008. e-Pub 2008.
      8. Saitta S, Pickering K, Gotter A, Hacker A, Nimmakayalu M, Goldmuntz E, Emanuel B. Molecular analysis of translocation breakpoints in a novel t(1;9) in a patient with isolated cardiac defect. American Journal of Human genetics, 2008. e-Pub 2008.
      9. Nimmakayalu MA, Emanuel BS, Tonk VS, Velagaleti GVN. Pericentric inv (22): Another low copy repeats (LCR) mediated recurrent abnormality?. Biennial American Cytogenetics Conference Cytogenetics and Genome research 106(1):131-131, 2004. e-Pub 2004.
      10. Nimmakayalu, Gotter AL, Emanuel BS. Analysis of a translocation breakpoint by FISH and PRINS: a molecular cytogenetic approach. American Journal of Human Genetics 73(5):306-306, 2003. e-Pub 2003.
      11. Ganesh J, Maisenbacher MK, Medne L, Moore EC, Nimmakayalu M, Moshang T, Zackai EH, Spinner NB. Phenotypic and Molecular characterization of distal 19q trisomy detected by FISH. American Journal of Human Genetics 73(5):289-289, 2003. e-Pub 2003.
      12. Nimmakayalu MA, Mack J, Qumsiyeh MB. Molecular characterization of microscopically visible deletion of 7q11.23 to q21.11. American Journal of Human Genetics 69(4):322-322, 2001. e-Pub 2001.
      13. Mack J, Nimmakayalu M, Pober B, Qumsiyeh MB. Mapping of a mosaic deletion of the short arm of chromosome 7 (7p15. 3 to 7p21. 1). American Journal of Human Genetics 69(4):321-321, 2001. e-Pub 2001.
      14. Nimmakayalu MA, Henegariu O, Bray-Ward P, Ward DC. A simple fluornucleotide coupling method for M-FISH analysis of patients associated with MR and Autism. American Journal of Human Genetics 65(4):A-352, 1999. e-Pub 1999.
      15. Alcassab H, Wu C, Kalia A, Nimmakayalu M, Liu X. Genomic Characterization of the T-ALL Cell Line CCRF-CEM Using Optical Genome Mapping and Nanopore Sequencing. Cancer Genetics Consortium.

      Book Chapters

      1. Verma IC, Sharma, V, Sarkar, T S, Kabra, M, Arya, L.S, Manjunath N A. Genetics studies of Retinoblastoma in India. In: Familial cancer and prevention: Molecular Epidemiology: A New strategy toward cancer Control. John Wiley & Sons, 485-491, 1999.
      2. I M Thomas, S Hegde, P. Tilak, S. Lincoln, K S Reddy, Manjunath N.A, S. Rajangam. Chromosomal Syndromes in Mental retardation - Role Of Genetics in Mental Retardation. Synergy Pub, 77-79, 1998.
      3. Nimmakayalu M. Cell – Organelles, division, technologies and the genome. In: The AGT Cytogenetics Laboratory Manual. Wiley Balckwell.

      Books (edited and written)

      1. Nimmakayalu M. The AGT Cytogenetics Laboratory Manual (New Edition). Wiley Blackwell.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top